Actively Recruiting
Phase I-II Study of HSV-tk Gene Therapy with Valacyclovir, Radiotherapy, and Chemotherapy for Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
Led by David Baskin MD · Updated on 2026-03-30
62
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and effectiveness of a combination treatment involving HSV-tk gene therapy, valacyclovir, radiotherapy, and chemotherapy for patients with recurrent glioblastoma multiforme or anaplastic astrocytoma who have not responded to standard treatments. This phase I-II study focuses on patients who previously underwent surgery and chemoradiation but experienced tumor recurrence. The study aims to evaluate the treatments impact on tumor progression, neurological function, and overall survival. During the study, the gene therapy HSV-tk is injected directly into the tumor during surgery. Within 24 hours, participants begin taking valacyclovir for 14 days. Radiotherapy is delivered in 10 sessions over two weeks, starting within nine days after surgery. Chemotherapy, which follows standard care, is given concurrently with or after radiotherapy based on clinical judgment. Patients may receive a second HSV-tk treatment six months after the first if appropriate. Participants will undergo neurological exams, cognitive testing, imaging studies, and blood tests to monitor immune response, blood counts, and liver function. Researchers will assess side effects using standard toxicity grading scales and observe median time to tumor progression and survival time, with follow-up lasting up to five years. The study includes ongoing assessments every 6 to 14 weeks to monitor disease status and patient health.
CONDITIONS
Brief Title
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
Research Team
D
David S Baskin, MD
H
Helga M Jones
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here